The Rheumatoid Arthritis Market Competitive Landscape and Clinical Stage Analysis

Rheumatoid arthritis, a systemic disease characterized by inflammation of the membrane lining the joint, is one of the most common forms of arthritis. Up to 50 percent of all rheumatoid arthritis patients enter early retirement within five years of diagnosis, which means that the indirect costs associated with this disease can be very high. While the prevalence of rheumatoid arthritis has decreased in recent years, partly due to stricter diagnosing criteria as well as other unknown factors, the higher uptake of rheumatoid arthritis therapies continues to represent a major commercial opportunity for pharmaceutical companies involved in the research and development of novel therapies for the disease.

The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis is an analytically-based overview of the current state of the global market for rheumatoid arthritis therapies, with a focus on the specific class of drugs, known as the biological response modifiers (BRMs). Biological response modifiers have revolutionized the treatment of rheumatoid arthritis, although their high cost (of up to $16,000 per patient per annum), has been a major point of contention for both Medicare reimbursement as well as private insurers. Consequently, an increasing amount of attention has been devoted to research into their cost-effectiveness as compared to other therapies, as well as one another. This report compares and contrasts the key rheumatoid arthritis therapies on the market as well as in research and development.

The report also offers a comprehensive overview of therapeutics currently in clinical development, with a view to assessing their impact on the future performance of leading rheumatoid arthritis drugs. As a class, biological response modifiers will, without a doubt, continue to make a major impact on the rheumatoid arthritis market. However, the leading drugs within this class are facing challenging times ahead, with a number of new products already reaching registration phases, led by Centocor/Schering-Plough’s Simponi and Celltech/UCB’s Cimzia.

The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis provides sales figures for major rheumatoid therapies, dating back to 2003, as well as sales forecasts through 2013. Apart from patent expirations facing current biological response modifiers and new product launches, which will increase price competition, there are a few other factors expected to slow down growth in this market during the next five years. For example, recent developments in the United Kingdom (UK) suggest that cost-containment may limit the use of expensive biologics if the first course of treatment fails. Similarly, a more intense scrutiny of adverse drug reactions may also limit this class’s reach in the market, although such issues will continue to be the driving force behind research into safer and more convenient methods of administration.

What Questions Does this Report Answer?

• What is the current competitive landscape of the rheumatoid arthritis market look like?
• What is the current status of emerging products with significant growth potential?
• What are the major clinical, economic and demographic drivers of the rheumatoid arthritis market?
• What does the future competitive landscape of the rheumatoid arthritis market look like?
• How will the issue of cost-effectiveness impact the future of the rheumatoid arthritis market?
• Will developmental-stage therapies be judged to a greater degree on the basis of cost-effectiveness in the near future?

Unique Features of this Report

• Clinically-based evaluation of leading rheumatoid arthritis therapies on the market and in development
• Identification of trends and issues that will have a significant impact on drug sales within the rheumatoid arthritis market.
• Market share metrics for key therapies as well as the overall rheumatoid arthritis market, by country/region
• Measurement of key clinical trials as a means of determining future success of product candidates in the market.
• SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis of leading rheumatoid arthritis therapies
• Forecasts of financial growth of this sector as a whole, as well as forecasts of revenue for key products in the field (all forecasts through 2013).

Highlights of this Report

• Discussion of rheumatoid arthritis therapies and their use in a number of key global markets.
• Discussion of the future of key rheumatoid arthritis therapies in light of scientific and medical developments.
• Focused analysis of various key R&D-stage therapies for rheumatoid arthritis.
• Identification of key trends within the rheumatoid arthritis market.

Reasons to Buy this Report

• The report provides an analysis-focused guide to the global market for rheumatoid arthritis therapeutics.
• The report provides important background about the disease, its etiology, patient population and financial and economic impact of the condition.
• The report provides a comparison of key rheumatoid arthritis therapies in a number of major markets.
• The report provides a scenario for the future use of leading rheumatoid arthritis therapies through the discussion of drivers and constraints.
• The report identifies key companies involved in the research and development of rheumatoid arthritis therapies.